Evaluating pain relief with Maxigesic in breast cancer surgery
Official title: Analgesic Efficacy of Maxigesic Added to Opioid Based-PCA in Patients Undergoing Breast Cancer Surgery
Run by Yonsei University · NCT06174363 · Data updated 2026-11-12
This study tests if Maxigesic can help relieve pain safely for people aged 20 to 70 undergoing breast cancer surgery while using less opioids.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 20 Years to 70 Years |
| Sex | Women only |
| Enrollment | 84 (estimated) |
| Sponsor | Yonsei University Academic / other |
| Locations | 1 site (Seoul) |
| Status | Recruiting |
| Started | December 28, 2023 |
| Main results expected | December 26, 2025 |
| Study ends | December 26, 2025 |
| Registry record updated | July 20, 2025 |
| Trial ID | NCT06174363 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients aged 20 to 70 with ASA classification 1 to 3 who are scheduled for breast cancer surgery.
✕Probably not a fit
Patients with ASA classification 4, allergies to study medications, severe liver or renal dysfunction, or those who are pregnant may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the effectiveness and safety of Maxigesic, a combination of acetaminophen and ibuprofen, as a perioperative analgesic for patients undergoing breast cancer surgery. The goal is to provide adequate pain relief while minimizing immune compromise associated with opioid use. Participants will receive Maxigesic in conjunction with opioid-based intravenous patient-controlled analgesia (IV-PCA) during their surgical procedure. The study focuses on patients aged 20 to 70 with specific health classifications undergoing cancer resection or reconstruction.
Why it matters
Potential benefit: If successful, this approach could lead to improved pain management and reduced opioid use in breast cancer surgery patients.
How similar studies have gone: Other studies have shown promising results with similar analgesic combinations, suggesting potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient aged 20 to 70 years with ASA classification 1 to 3 undergoing breast cancer surgery (cancer resection or reconstruction) Exclusion Criteria: * ASA classification 4/ allergy to acetaminophen, NSAIDs, opioid/ severe liver or renal dysfunction/ pregnancy
Where it's running
-
Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine
Seoul, South Korea Recruiting
Study contacts
- Study coordinator: Jin Sun Cho
- Email: chjs0214@yuhs.ac
- Phone: 82-2-2228-2419
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.